Who qualifies for Accutane (and who doesn’t)?
Who qualifies for Accutane under the 2024 AAD guideline and FDA label: hormonal acne, men, body acne, adults, and why blackheads and pores don’t. Read more →
Who qualifies for Accutane under the 2024 AAD guideline and FDA label: hormonal acne, men, body acne, adults, and why blackheads and pores don’t. Read more →
When telehealth Accutane (isotretinoin) is a fit and when in-person dermatology is the better route, plus what iPledge requires either way. Read more →
Does Accutane work for hormonal acne, and does a low dose suit mild acne? What the FDA label, the AAD and verified trials say. Read more →
Second course of Accutane: verified relapse rates, why total dose beats daily dose, and why a low-dose second course means more iPledge months. Read more →
Low dose Accutane side effects, effect by effect: what studies show gets milder, what stays the same at any dose, and why iPledge never shrinks. Read more →
What low-dose isotretinoin results look like month by month, what one 50-patient study measured, and why a gentler course means more iPledge cycles, not fewer. Read more →
What microdosing Accutane actually means, what one clinical study found, and the detail every guide skips: your iPledge requirements don’t shrink with your dose. Read more →
Low dose Accutane vs standard isotretinoin: a dermatology-informed breakdown of dosing, side effects, timelines, cost, and who each approach is right for. Read more →
What the Accutane label, the AAD and a 2024 meta-analysis say about isotretinoin and mood, plus the signs that mean stop and call your prescriber. Read more →
Brand Accutane is no longer available in the US. Here is what the FDA, DailyMed labels and the AAD say about generic isotretinoin, food instructions, cost and iPLEDGE. Read more →